Analyst commentary on Dexcom stock forecast 2025 cites strong retention rates among users, which enhances predictability in future cash flows. “While we anticipate additional remediation expenses throughout the year (similar to iRhythm’s approximately $15m expected in 2025), we believe margins should not be meaningfully impacted,” the report added. DexCom delivered a solid second-quarter update, marked by double-digit top-line growth and a confident raise in full-year guidance, as it executes on broadening access to CGM and scaling its innovation engine. For growth investors, Dexcom stock forecast 2025 is supported by continued expansion in subscription models, creating steady ARR (Annual Recurring Revenue).
